 |
2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant melanoma stages IIb through IV |
| USA Market Approval | USA |
| USA Designation Date | 2007-12-18 00:00:00 |
| Sponsor | AbbVie, Inc.;1 N. Waukegan Road;North Chicago, Illinois, 60064 |
